AbbVie (ABBV - Free Report) closed the most recent trading day at $92.05, moving -0.51% from the previous trading session. The stock lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
Coming into today, shares of the drugmaker had lost 4.6% in the past month. In that same time, the Medical sector gained 3.21%, while the S&P 500 gained 2.79%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be November 2, 2018. The company is expected to report EPS of $2.01, up 42.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.20 billion, up 17.19% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.86 per share and revenue of $32.89 billion, which would represent changes of +40.36% and +16.55%, respectively, from the prior year.
Any recent changes to analyst estimates for ABBV should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, ABBV is holding a Forward P/E ratio of 11.79. This valuation marks a discount compared to its industry's average Forward P/E of 16.61.
Investors should also note that ABBV has a PEG ratio of 0.89 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 1.99 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AbbVie (ABBV - Free Report) closed the most recent trading day at $92.05, moving -0.51% from the previous trading session. The stock lagged the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
Coming into today, shares of the drugmaker had lost 4.6% in the past month. In that same time, the Medical sector gained 3.21%, while the S&P 500 gained 2.79%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be November 2, 2018. The company is expected to report EPS of $2.01, up 42.55% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.20 billion, up 17.19% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.86 per share and revenue of $32.89 billion, which would represent changes of +40.36% and +16.55%, respectively, from the prior year.
Any recent changes to analyst estimates for ABBV should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ABBV is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, ABBV is holding a Forward P/E ratio of 11.79. This valuation marks a discount compared to its industry's average Forward P/E of 16.61.
Investors should also note that ABBV has a PEG ratio of 0.89 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 1.99 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 58, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ABBV - FREE